A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago

Trial Profile

A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 May 2016

At a glance

  • Drugs Cyclobenzaprine/meloxicam (Primary) ; Cyclobenzaprine; Meloxicam
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Eurofarma
  • Most Recent Events

    • 29 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment because the comparator product was withdrawn from the brazilian market not being possible to conduct the design regarding initially planned
    • 24 Jul 2015 Planned primary completion date changed from 1 Jun 2013 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
    • 24 Jul 2015 Planned End Date changed from 1 Sep 2013 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top